Who is sponsoring NCT03305341?

NCT03305341 is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.

Is NCT03305341 still recruiting?

NCT03305341 is currently active, enrolled. Last updated 11 June 2025.

Last reviewed 2025-06-11 · How we verify

NCT03305341: COVSP-BCG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

Active, enrolled EARLY_PHASE1 Last updated 11 June 2025

What this trial tests

EARLY_PHASE1 trial testing COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use in Covid19 in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 May 2025

Primary endpoint
18 July 2026

28 July 2026

Quick facts

Lead sponsor	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	20
Start date	18 May 2025
Primary completion	18 July 2026
Estimated completion	28 July 2026
Sites	1 location across United States

Drugs / interventions tested

COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — full company profile →

Who can join

Adults 24 to 64, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The 2020 race towards SARS-CoV-2 specific vaccines.
Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, et al · · 2021 · cited 65× · PMID 33408775 · DOI 10.7150/thno.53691
Principles and Challenges in anti-COVID-19 Vaccine Development.
Strizova Z, Smetanova J, Bartunkova J, Milota T. · · 2021 · cited 29× · PMID 33524979 · DOI 10.1159/000514225
Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).
Wang X, He Z, Zhao X. · · 2021 · cited 8× · PMID 33732292 · DOI 10.3892/etm.2021.9750

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
NCT04802408 — SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial · Phase 2, PHASE3 · active not recruiting

Other Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair trials

Trials by the same sponsor.

NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07182838 — Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT07145333 — Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT01064466 — Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT06062810 — Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03305341 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Last refreshed: 11 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03305341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing